Cardiovascular Systems Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (27)

View All

Latest Posts

About This Stock More About This Stock
4 Big Winners Of Trump's Healthcare Plan
Article By: Swarup Gupta
Sunday, March 12, 2017 5:08 PM EDT
New healthcare legislation has its own sets of winners and losers and the sector as a whole continues to remain strong. This means that it’s a good idea to pick those stocks which are poised to gain from the new healthcare law.
In this article: LCI, CSII, OSUR, INGN Also: AET, BSX, CNC, CYH, EW, HUM, MOH, THC, UNH, WCG, IYH
Read
Medical Tech M&A Analysis: Cardio And Vascular
Article By: Joe Kunkle
Wednesday, June 8, 2016 4:56 AM EDT
In breaking down prospective M&A targets in the Cardio and Vascular focus area within Med-Tech, Cardiovascular Systems (CSII) looks to be the most compelling play.
In this article: CSII, ABT, BSX, EW, MDT, STJ, ATRC, ELGX, HTWR, SPNC, VASC, MMSI, LDRH, ZBH
Read
Rayno Life Sciences DX And Tools Update: 2015 Q1 Winners ALR,FMI,HOLX
Article By: Rod Raynovich
Friday, March 13, 2015 6:37 AM EDT
Here are the 2015 YTD top five winners among our focus stocks...
In this article: ABAX, ALR, CSII, FMI, HOLX
Read
Rayno Dx And Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR
Article By: Rod Raynovich
Thursday, February 19, 2015 4:41 PM EDT
Major ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%.
In this article: FMI, CSII, HOLX, ALR, FBT, IBB, XBI, CPHD, ILMN, ABAX, QGEN, TMO, EXAS, GHDX, NEOG, NSTG, PACB, QDEL, SQNM, VRML
Read
Boston Scientific Tops Q4 Earnings, Revenues Miss Mark
Article By: Zacks Investment Research
Wednesday, February 4, 2015 12:11 PM EDT
Boston Scientific Corporation (BSX) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 15 cents in the fourth quarter of 2014, 15.4% ahead of the year-ago adjusted number.
In this article: BSX, ABAX, CSII, ICUI
Read
All Posts

Latest Tweets for $CSII

No tweets yet!

PARTNER HEADLINES